Investing.com – U.S. stocks were lower after the close on Friday, as losses in the Basic Materials, Utilities and Technology sectors led shares lower. At the close in NYSE, the...
On the 31st of March, Arrowpoint Asset Management bought 2.3 million 2U, Inc. (NASDAQ:TWOU) shares for $88 million at an average price of $38.23 per share. Shares of 2U, Inc. are...
TCR² Therapeutics Inc. (NASDAQ:TCRR) has been struggling lately, but the selling pressure may be coming to an end soon. That is because TCRR recently saw a Hammer Chart...
As of late, it has definitely been a great time to be an investor in TCR2 Therapeutics Inc. (NASDAQ:TCRR) . The stock has moved higher by 45.3% in the past month, while it is also...
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company’s lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
|Average||12.78 (+622.03% Upside)|
|No. of Analysts||9|